

MD Anderson at the 2020 ASCO Annual Meeting

May 29-31, 2020

THE UNIVERSITY OF TEXAS
MD Anderson
~~Cancer Center~~
Making Cancer History®

| STREAMING PRESENTATIONS | | | |
|------------------------------------|--|--|---------------------------------|
| Saturday, May 30 | | | |
| 1:00 – 2:30 p.m. EDT | Special Clinical Science Symposium Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors | <i>Discussion: Tumor-Specific Vaccines: Lessons Learned from HPV</i> | Michael A. Curran, Ph.D. |
| 1:00 – 2:30 p.m. EDT | Special Clinical Science Symposium Harnessing Immunotherapy with Novel Approaches Beyond Checkpoint Inhibitors | <i>102: Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors</i> | David S. Hong, M.D. |
| Sunday, May 31 | | | |
| 10:30 a.m. – 12:00 p.m. EDT | Special Clinical Science Symposium Drug Development for Rare Mutations: The Opportunity to Unite and Conquer! | <i>109: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors</i> | Vivek Subbiah M.D. |
| 1:00 – 3:00 p.m. EDT | Plenary Session | <i>Discussion of LBA4: Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study</i> | Michael J. Overman, M.D. |

| ON-DEMAND CLINICAL SCIENCE SYMPOSIUM PRESENTATIONS | | |
|--|---|-------------------------------|
| Tumor Intrinsic and Extrinsic Factors Affecting Immunotherapy Response in Head and Neck Cancer | <i>Discussion: Of Bugs and Drugs: How Our Microbiome Saves Us</i> | Ann Klopp, M.D., Ph.D. |

| ON-DEMAND ORAL PRESENTATIONS | | |
|--|--|---|
| Cancer Prevention, Risk Reduction, and Genetics | <i>Discussion: Seek and Ye Shall Find: Germline Mutations in Somatic Profiling</i> | Funda Meric-Bernstam, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>3008: Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.</i> | Benjamin Garmezy, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>Discussion: Using Genomics to Select for Checkpoint Blockade</i> | Ferdinandos Skoulidis, M.D., Ph.D. |
| Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | <i>3506: Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.</i> | Senthil Damodaran, M.D. Ph.D. |
| Gastrointestinal Cancer—Colorectal and Anal | <i>4001: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).</i> | Scott Kopetz, M.D. Ph.D. |
| Genitourinary Cancer—Kidney and Bladder | <i>5003: Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.</i> | Eric Jonasch, M.D. |
| Genitourinary Cancer—Prostate, Testicular, and Penile | <i>5504: Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).</i> | Eleni Efstathiou, M.D. Ph.D. |
| Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>7500: Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.</i> | Curtis Lachowicz, M.D. |

| | | |
|--|--|------------------------------------|
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft | <i>7501: Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).</i> | Courtney Dinardo M.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft | <i>7508: Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).</i> | Farhad Ravandi, M.D. |
| Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia | <i>8002: First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.</i> | Sattva Neelapu, M.D. |
| Hematologic Malignancies— Plasma Cell Dyscrasia | <i>Discussion: Guns N' Roses: CAR T in Multiple Myeloma</i> | Krina K. Patel, M.D. |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>Discussion: Limited-Stage Small Cell Lung Cancer: Have We Finally Defined Radiation Standards?</i> | Percy Lee, M.D. |
| Melanoma/Skin Cancers | <i>10008: Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).</i> | Isabella Glitza, M.D. Ph.D. |
| Melanoma/Skin Cancers | <i>Discussion: Adjuvant and Neoadjuvant Therapies in 2020</i> | Rodabe Amaria, M.D. |
| Pediatric Oncology I | <i>10508: Phase II study of antidiialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children's Oncology Group.</i> | Pooja Hingorani, M.D. |
| Sarcoma | <i>11505: Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).</i> | Christina Roland, M.D. |
| Symptoms and Survivorship | <i>12006: Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit: A double-blind randomized clinical trial.</i> | David Hui, M.D. |

| ON-DEMAND POSTER DISCUSSION PRESENTATIONS | | |
|---|--|---------------------------------------|
| Breast Cancer— Local/Regional/Adjuvant | <i>509: Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).</i> | Clinton Yam, M.D. |
| Breast Cancer— Local/Regional/Adjuvant | <i>517: Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.</i> | Bora Lim, M.D. |
| Breast Cancer—Metastatic | <i>1018: Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).</i> | Jennifer Litton, M.D. |
| Care Delivery and Regulatory Policy | <i>Discussion: Using Patient-Reported Outcomes to Inform Clinical Trials and Clinical Practice</i> | Ishwaria M. Subbiah, M.D. |
| Care Delivery and Regulatory Policy | <i>2020 : Absence of optimism bias in industry-sponsored cancer trials.</i> | Sonal Noticewala, M.D. |
| Central Nervous System Tumors | <i>2511: Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).</i> | Shiao-Pei Weathers, M.D. |
| Central Nervous System Tumors | <i>2515: A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function.</i> | Shiao-Pei Weathers, M.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>3511: CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).</i> | David S. Hong, M.D. |
| Genitourinary Cancer—Kidney and Bladder | <i>5015 : ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.</i> | Arlene O. Siefker-Radtke, M.D. |
| Genitourinary Cancer— Prostate, Testicular, and Penile | <i>Discussion: Promising Therapeutic Targets in Prostate Cancer</i> | Ana Aparicio, M.D. |

| | | |
|--|--|----------------------------------|
| Head and Neck Cancer | <i>6514 : Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).</i> | Maria E. Cabanillas, M.D |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft | <i>7519: Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.</i> | Abhishek Maiti, M.D |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allograft | <i>7512 : Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).</i> | Nitin Jain, M.D |
| Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia | <i>8011: Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).</i> | Paolo Strati, M.D |
| Hematologic Malignancies— Plasma Cell Dyscrasia | <i>8519: DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.</i> | Hans C. Lee, M.D |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>9013: A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma.</i> | Kanwal Raghav, M.D. |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>Discussion: Small Cell Lung Cancer: Moving Toward Precision Oncology</i> | Lauren A. Byers, M.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>9514: Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.</i> | Xiuning Le, M.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>9516: Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.</i> | Vivek Subbiah, M.D. |
| Sarcoma | <i>11509: A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.</i> | Neeta Somaiah, M.D. |
| Sarcoma | <i>11517: A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma.</i> | Vinod Ravi, M.D. |
| Symptoms and Survivorship | <i>12021: Integrating PROs with prognostic value into oncologic care: High ESAS global distress score associated with lower overall survival in advanced cancer patients.</i> | Ishwaria M. Subbiah, M.D. |

| ON-DEMAND POSTER PRESENTATIONS | | |
|---|---|---------------------------------------|
| Breast Cancer— Local/Regional/Adjuvant | 576: <i>Re-excision rates among older breast cancer patients undergoing breast-conserving surgery (BCS): Impact of the SSO-ASTRO consensus guideline on margins.</i> | Mariana Chavez-MacGregor, M.D. |
| Breast Cancer— Local/Regional/Adjuvant | 595: <i>Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC).</i> | Stacy L. Moulder, M.D. |
| Breast Cancer— Local/Regional/Adjuvant | 583 : <i>Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC).</i> | Nour Abuhadra, M.D. |
| Breast Cancer—Metastatic | 1039: <i>A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.</i> | Funda Meric-Bernstam, M.D. |
| Breast Cancer—Metastatic | 1096: <i>The incidence and impact of brain metastasis in patients with hereditary BRCA1/2 mutated invasive breast cancer in a prospectively followed cohort.</i> | Haven Garber, M.D. |
| Cancer Prevention, Risk Reduction, and Genetics | 1544: <i>Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort.</i> | Banu Arun, M.D. |
| Cancer Prevention, Risk Reduction, and Genetics | 1546: <i>Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial.</i> | Banu Arun, M.D. |
| Care Delivery and Regulatory Policy | 2047: <i>Machine learning algorithms to predict financial toxicity associated with breast cancer treatment.</i> | Chris Sidey-Gibbons, Ph.D. |
| Care Delivery and Regulatory Policy | TPS2088: <i>Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs).</i> | Pavlos Msaouel, M.D., Ph.D. |
| Care Delivery and Regulatory Policy | TPS2089: <i>ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).</i> | Matthew Campbell, M.D. |

| | | |
|--|---|--|
| Central Nervous System Tumors | <i>2531: Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: A phase I trial.</i> | Jing Li, M.D., Ph.D. |
| Central Nervous System Tumors | <i>2559: Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.</i> | Nazanin Majd, M.D., Ph.D. |
| Developmental Therapeutics—Immunotherapy | <i>3023: Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.</i> | Michael Wang, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>3027: Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method.</i> | Meredith Pelster, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>3067: Fecal microbiota transplantation (FMT) for immune checkpoint inhibitor induced–colitis (IMC) refractory to immunosuppressive therapy.</i> | Yinghong Wang, M.D., Ph.D. |
| Developmental Therapeutics—Immunotherapy | <i>3143: Percutaneous hepatic injection of rose bengal disodium (PV-10) in metastatic uveal melanoma.</i> | Sapna Patel, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>TPS3156: A phase II study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007.</i> | Timothy A. Yap, M.D., Ph.D. |
| Developmental Therapeutics—Immunotherapy | <i>TPS3158: A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).</i> | Ecaterina Ileana Dumbrava, M.D. |
| Developmental Therapeutics—Immunotherapy | <i>TPS3162: A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.</i> | Filip Janku, M.D., Ph.D. |
| Developmental Therapeutics—Immunotherapy | <i>TPS3165: A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).</i> | George Blumenschein, M.D. |
| Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | <i>3587: AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors.</i> | Timothy A. Yap, M.D., Ph.D. |

| | | |
|---|--|---|
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>3629: Identifying functional loss of ATM gene in patients with advanced cancer.</i> | Patrick Pilie, M.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>3640: Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.</i> | Filip Janku, M.D., Ph.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>TPS3645: A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases.</i> | Nancy Gordon, M.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>TPS3657: A phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors.</i> | Apostolia Tsimberidou, M.D., Ph.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>TPS3658: A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC).</i> | Apostolia Tsimberidou, M.D., Ph.D. |
| Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology | <i>TPS3663: A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET.</i> | David S. Hong, M.D. |
| Gastrointestinal Cancer— Colorectal and Anal | <i>4039: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).</i> | Scott Kopetz, M.D., Ph.D. |
| Gastrointestinal Cancer— Colorectal and Anal | <i>4047: Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.</i> | Van K. Morris, M.D. |
| Gastrointestinal Cancer— Colorectal and Anal | <i>4089: Consensus molecular subtypes (CMS) as a marker for treatment and disease biology in metastatic colorectal cancer (CRC).</i> | Michael Lam, M.D. |
| Gastrointestinal Cancer— Colorectal and Anal | <i>4084 : Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: A phase II trial of bintrafusp alfa in CMS4 metastatic CRC.</i> | Amir Mehrvarz Sarshekeh, M.D. |
| Gastrointestinal Cancer— Colorectal and Anal | <i>TPS4121: Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).</i> | Van K. Morris, M.D. |

| | | |
|--|--|-------------------------------------|
| Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary | <i>4591: A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.</i> | Milind M. Javle, M.D. |
| Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary | <i>4597: Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).</i> | Milind M. Javle, M.D. |
| Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary | <i>4599: Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.</i> | Ahmed Kaseb, M.D. |
| Gastrointestinal Cancer— Gastroesophageal, Pancreatic, and Hepatobiliary | <i>4610: Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).</i> | Arvind Dasari, M.D. |
| Genitourinary Cancer—Kidney and Bladder | <i>5029: Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials.</i> | Omar Alhalabi, M.D. |
| Genitourinary Cancer—Kidney and Bladder | <i>5049: Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.</i> | Elishad Hasanov, M.D., Ph.D. |
| Genitourinary Cancer—Kidney and Bladder | <i>5073: Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).</i> | Andrew Hahn, M.D. |
| Gynecologic Cancer | <i>6063: Are symptoms distinguishable in ovarian cancer? A nested case control study of insurance claims.</i> | Denise Langabeer, Ph.D. |
| Gynecologic Cancer | <i>6079: Financial toxicity and patient-reported outcomes over time: A longitudinal study of women with recurrent ovarian cancer.</i> | Larissa Meyer, M.D. |
| Gynecologic Cancer | <i>6085: An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.</i> | Filip Janku, M.D., Ph.D. |
| Gynecologic Cancer | <i>TPS6108: DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).</i> | Shannon N. Westin, M.D. |

| | | |
|--|---|-------------------------------------|
| Head and Neck Cancer | <i>6578: Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study.</i> | Gary Brandon Gunn, M.D. |
| Head and Neck Cancer | <i>TPS6590: Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.</i> | Faye M. Johnson, M.D., Ph.D. |
| Health Services Research and Quality Improvement | <i>7050: Prior authorization process improvement for pain medications in an oncology unit: Timely initiation of test claim request form.</i> | Susy Varghese, D.N.P. |
| Health Services Research and Quality Improvement | <i>7082: Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials.</i> | Ryan Huey, M.D. |
| Health Services Research and Quality Improvement | <i>7083 : Financial burden of discarded weight-based cancer drugs to payers and patients in private insurance market.</i> | Ya-Chen (Tina) Shih, Ph.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>7521: Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML).</i> | Courtney Dinardo, M.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>7530: CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.</i> | Farhad Ravandi, M.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>7539: Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).</i> | Tapan M. Kadia, M.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>TPS7561: A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies.</i> | Maro Ohanian, D.O. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>TPS7563: A phase I/II study of IMG632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.</i> | Naval Daver, M.D. |
| Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant | <i>TPS7564: A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMG632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.</i> | Naval Daver, M.D. |

| | | |
|---|--|---|
| Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia | <i>8036: Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).</i> | Hun Ju Lee, M.D. |
| Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia | <i>8057: Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).</i> | Sairah Ahmed, M.D. |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>9035: I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.</i> | Joe Y. Chang, M.D., Ph.D. |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>9024 : Validation of 4-marker protein panel for the early detection of lung cancer using PLCO samples.</i> | Johannes Fahrman, Ph.D. |
| Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | <i>TPS9076: Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.</i> | Tina Cascone, M.D., Ph.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>9548: Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials.</i> | James Welsh, M.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>9556: Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.</i> | Xiuning Le, M.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>9624: BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC.</i> | Yasir Elamin, M.D. |
| Lung Cancer—Non-Small Cell Metastatic | <i>TPS9627: A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).</i> | Ferdinandos Skoulidis, M.D., Ph.D. |
| Melanoma/Skin Cancers | <i>10033: Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.</i> | Michael R. Migden, M.D. |
| Melanoma/Skin Cancers | <i>10072: KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti-PD-1/L1 immunotherapy.</i> | Michael K. Wong, M.D., Ph.D. |

| | | |
|---------------------------|---|----------------------------------|
| Melanoma/Skin Cancers | <i>TPS10090: S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma.</i> | Sapna Patel, M.D. |
| Sarcoma | <i>TPS11569: SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.</i> | Dejka M. Araujo, M.D. |
| Symptoms and Survivorship | <i>12072: Patient reported outcomes in older breast cancer survivors.</i> | Sharon H. Giordano, M.D. |
| Symptoms and Survivorship | <i>12077: High flow oxygen for dyspnea in hospitalized patients with cancer: A 4x4 crossover randomized clinical trial.</i> | David Hui, M.D. |
| Symptoms and Survivorship | <i>12086: Frequency and prediction of non-medical opioid use behaviors (NMOU) among advanced cancer patients referred to a supportive care center (SCC).</i> | Sriram Yennu, M.D. |
| Symptoms and Survivorship | <i>12044 : Investigating the disparate enrollment of older adults on phase I clinical trials: Evolving participation patterns of patients 65 years and older w advanced cancer on phase I trials.</i> | Ishwaria M. Subbiah, M.D. |